Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF), a clinical-stage biotech company specializing in nanotechnology-driven cancer treatments, has reached a significant milestone with the initiation of its first human clinical trial for a novel targeted hyperthermia therapy (THT). The therapy aims to convert “cold” tumors — which typically evade immune detection — into “hot” tumors that respond to immunotherapy, potentially overcoming one of oncology’s most stubborn challenges.
Speaking to investors recently, CEO David Regan described the journey from concept to clinical trial as a transformative two-year effort. “We’re incredibly proud to be speaking to you today in the midst of our first human clinical trial for our targeted hyperthermia therapy—an exciting milestone for Sona,” he said.
At the heart of Sona’s approach lies a proprietary gold nanorod technology that is biocompatible and responsive to near-infrared light. Unlike conventional nanorod nanoparticles, the manufacturing of these gold nanorods avoids toxic surfactants, a biocompatibility feature validated by the US Nanotechnology Characterization Laboratory, an organization supported by the FDA and National Cancer Institute.
Turning cold tumors hot
Immunotherapy has revolutionized cancer treatment but remains effective primarily in patients with “hot” tumors — those that provoke an immune response. The majority of tumors, however, are “cold” and evade immune detection, rendering many immunotherapies ineffective.
Sona’s THT aims to solve this by injecting gold nanorods directly into tumors. Once localized, near-infrared light heats the particles to a mild fever-like temperature (42–48°C), inducing controlled cell death (apoptosis) and activating immune cells. This subtle heat stress modifies the tumor microenvironment, awakening the immune system without damaging healthy cells which are more resilient to heat.
At the same time, immunologist Dr David Conrad highlighted the rigor of Sona’s preclinical work. The therapy demonstrated consistent efficacy across multiple “cold” tumor models in genetically distinct mouse strains, including colorectal, triple-negative breast cancer, and melanoma models.
“That consistency strengthens the argument that this is a generalizable mechanism,” Conrad said, noting that success across diverse models bodes well for translation to genetically varied human populations.
First-in-human trial in Chile
The ongoing early feasibility study is underway at Bradford Hill, an oncology clinic in Chile known for expertise in immunotherapy. Chile’s regulatory environment, public healthcare coverage of immunotherapy, and patient population (notably a high incidence of melanoma) make it an ideal trial location.
The trial’s primary goals are to evaluate safety, tolerability, and biological evidence of immune activation in 10 patients with late-stage metastatic melanoma unresponsive to standard treatments. Treatments occur on Days 1 and 8, with biopsies and blood sampling to assess changes in the tumor microenvironment.
“We’ve shown safety in the lab—now we’re translating it to the human environment,” Giacomantonio said.
Treatments address both surface and deeper tumors, using aloe vera gel to protect skin during surface lesion exposure and precise laser alignment for deeper tissue. Early treatment sessions have lasted up to 2.5 hours for up to four lesions, a duration considered tolerable and comparable to other imaging procedures.
Training clinic staff has been a priority to ensure the procedure’s safe and consistent application. Giacomantonio described the first injection of gold nanorods into a human tumor as a “powerful milestone.”
Measuring success
The trial will carefully monitor for safety and patient tolerability, but also seek signs of immune system activation. Biopsies are analyzed for immune cell infiltration — a hallmark of “hot” tumors. The team is mindful of “pseudoprogression,” a phenomenon where tumors temporarily swell due to immune infiltration, not growth, which complicates interpretation.
Following this 10-patient study, Sona plans a larger pilot trial of 30 to 40 patients in Canada in early 2026, managed internally to optimize costs and efficiency. Eventually, a pivotal trial with 100 to 200 patients is anticipated.
The company is also investigating additional cancer types, including squamous cell carcinoma, glioblastoma, breast, colorectal, bladder cancers, and bone metastases. Engineering and biological challenges remain, but the potential for broad application is high.
Sona’s leadership is cautiously optimistic. Regan remarked, “We’re not claiming victory yet, but we believe this therapy has real potential to move the yard marker for cancer treatment.”
Towards a new cancer paradigm
Beyond THT, Sona is developing theranostic applications — combining diagnostics with therapy — and triconjugate payloads to deliver drugs directly into tumors via the nanorods. Several provisional patents have been filed in these areas, suggesting a platform with multiple future pathways.
Dr Conrad summarized the approach succinctly: “Instead of making a bigger hammer, they are making the nail easier to see.”
By modulating the tumor microenvironment locally and enhancing immune response, Sona Nanotech’s targeted hyperthermia therapy could redefine cancer treatment, offering a path to safer and more effective immunotherapies.